Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial.

Liao M, Li X, Zhang H, Zhou L, Shi L, Li W, Shen R, Peng G, Zhao H, Shao J, Wang X, Sun Z, Zheng H, Long M

Endocrine31 Aug 2023Cited by 21 (Europe PMC)

PMID37653215PMCIDPMC10806039DOI10.1007/s12020-023-03487-4PepBankPUB-37653215

Summary

PurposePolycystic ovary syndrome (PCOS) is characterized by reproductive dysfunctions and metabolic disorders. This study aims to compare the therapeutic effectiveness of glucagon-like peptide-1 receptor agonist (GLP-1RA) + Metformin (Met) versus cyproterone acetate/ethinylestradiol (CPA/EE) + Met in overweight PCOS women and identify potential proteomic biomarkers of disease risk in women with PCOS.MethodsIn this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks. The clinical effectiveness and adverse effects were evaluated, followed by plasma proteomic analysis and verification of critical biomarkers by ELISA.ResultsEighty(80%) patients completed the study. Both interventions improved menstrual cycle, polycystic ovaries, LH(luteinizing hormone) and HbA1c(hemoglobin A1c) levels after the 12-week treatment. GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI (Body Mass Index), and waist circumference, FBG(fasting blood glucose), AUCI(area under curve of insulin),TC (Total Cholesterol), IL-6(Interleukin-6) and improving insulin sensitivity, and ovulation in overweight women with PCOS, with acceptable short-term side effects. CPA/EE + Met was more effective in improving hyperandrogenemia, including T(total testosterone), LH, LH/FSH(Luteinizing hormone/follicle-stimulating hormone), SHBG(sex hormone-binding globulin) and FAI (free androgen index). By contract, GLP-1RA+Met group only improved LH. Plasma proteomic analysis revealed that the interventions altered proteins involved in reactive oxygen species detoxification (PRDX6, GSTO1, GSTP1, GSTM2), platelet degranulation (FN1), and the immune response (SERPINB9).ConclusionsBoth CPA/EE+Met and GLP-1RA + Met treatment improved reproductive functions in overweight PCOS women. GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI, and waist, and improving metabolism, and ovulation in overweight women with PCOS, with acceptable short-term side effects. CPA/EE + Met was more effective in reducing hyperandrogenemia. The novel plasma biomarkers PRDX6, FN1, and SERPINB9, might be indicators and targets for PCOS treatment. TRIAL REGISTRATION CLINICALTIALS.Gov trial noNCT03151005. Registered 12 May, 2017, https://clinicaltrials.gov/ct2/show/NCT03151005 .

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study16

15 results from studies that gave the peptide. 15 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, liraglutide plus metformin improved the menstrual cycle after 12 weeks.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin improved the menstrual cycle.
Peptide
Liraglutide
Outcome
Direction not reportedMenstrual cycle
Study
n = 60
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
Both interventions improved menstrual cycle, polycystic ovaries, LH(luteinizing hormone) and HbA1c(hemoglobin A1c) levels after the 12-week treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321501
02HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, liraglutide plus metformin improved polycystic ovaries after 12 weeks.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin improved polycystic ovaries.
Peptide
Liraglutide
Outcome
Direction not reportedPolycystic ovaries
Study
n = 60
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
Both interventions improved menstrual cycle, polycystic ovaries, LH(luteinizing hormone) and HbA1c(hemoglobin A1c) levels after the 12-week treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321502
03HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, luteinizing hormone improved with liraglutide plus metformin after 12 weeks.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin improved luteinizing hormone levels.
Peptide
Liraglutide
Outcome
DecreaseLuteinizing hormone
Study
n = 60
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
Both interventions improved menstrual cycle, polycystic ovaries, LH(luteinizing hormone) and HbA1c(hemoglobin A1c) levels after the 12-week treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321503
04HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, HbA1c improved with liraglutide plus metformin after 12 weeks.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin improved HbA1c.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n = 60
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
Both interventions improved menstrual cycle, polycystic ovaries, LH(luteinizing hormone) and HbA1c(hemoglobin A1c) levels after the 12-week treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321504
05HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, liraglutide plus metformin reduced body weight more than CPA/EE plus metformin.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin reduced body weight more than CPA/EE plus metformin.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 60
Comparator
CPA/EE + metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI (Body Mass Index), and waist circumference, FBG(fasting blood glucose), AUCI(area under curve of insulin),TC (Total Cholesterol), IL-6(Interleukin-6) and improving insulin sensitivity, and ovulation in overweight women with PCOS, with acceptable short-term side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321505
06HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, liraglutide plus metformin reduced BMI more than CPA/EE plus metformin.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin lowered BMI more than CPA/EE plus metformin.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n = 60
Comparator
CPA/EE + metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI (Body Mass Index), and waist circumference, FBG(fasting blood glucose), AUCI(area under curve of insulin),TC (Total Cholesterol), IL-6(Interleukin-6) and improving insulin sensitivity, and ovulation in overweight women with PCOS, with acceptable short-term side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321506
07HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, liraglutide plus metformin reduced waist circumference more than CPA/EE plus metformin.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin reduced waist size more than CPA/EE plus metformin.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n = 60
Comparator
CPA/EE + metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI (Body Mass Index), and waist circumference, FBG(fasting blood glucose), AUCI(area under curve of insulin),TC (Total Cholesterol), IL-6(Interleukin-6) and improving insulin sensitivity, and ovulation in overweight women with PCOS, with acceptable short-term side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321507
08HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, liraglutide plus metformin reduced fasting blood glucose more than CPA/EE plus metformin.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin lowered fasting glucose more than CPA/EE plus metformin.
Peptide
Liraglutide
Outcome
DecreaseFasting blood glucose
Study
n = 60
Comparator
CPA/EE + metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI (Body Mass Index), and waist circumference, FBG(fasting blood glucose), AUCI(area under curve of insulin),TC (Total Cholesterol), IL-6(Interleukin-6) and improving insulin sensitivity, and ovulation in overweight women with PCOS, with acceptable short-term side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321508
09HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, liraglutide plus metformin reduced the insulin area under the curve more than CPA/EE plus metformin.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin lowered insulin exposure after glucose more than CPA/EE plus metformin.
Peptide
Liraglutide
Outcome
DecreaseArea under the insulin curve (AUCI)
Study
n = 60
Comparator
CPA/EE + metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI (Body Mass Index), and waist circumference, FBG(fasting blood glucose), AUCI(area under curve of insulin),TC (Total Cholesterol), IL-6(Interleukin-6) and improving insulin sensitivity, and ovulation in overweight women with PCOS, with acceptable short-term side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321509
10HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, liraglutide plus metformin reduced total cholesterol more than CPA/EE plus metformin.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin lowered total cholesterol more than CPA/EE plus metformin.
Peptide
Liraglutide
Outcome
DecreaseTotal cholesterol
Study
n = 60
Comparator
CPA/EE + metformin
Outcome group
Lipids · Metabolic and weight
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI (Body Mass Index), and waist circumference, FBG(fasting blood glucose), AUCI(area under curve of insulin),TC (Total Cholesterol), IL-6(Interleukin-6) and improving insulin sensitivity, and ovulation in overweight women with PCOS, with acceptable short-term side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321510
11HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, liraglutide plus metformin reduced IL-6 more than CPA/EE plus metformin.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin lowered IL-6 more than CPA/EE plus metformin.
Peptide
Liraglutide
Outcome
DecreaseInterleukin-6
Study
n = 60
Comparator
CPA/EE + metformin
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI (Body Mass Index), and waist circumference, FBG(fasting blood glucose), AUCI(area under curve of insulin),TC (Total Cholesterol), IL-6(Interleukin-6) and improving insulin sensitivity, and ovulation in overweight women with PCOS, with acceptable short-term side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321511
12HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, liraglutide plus metformin improved insulin sensitivity more than CPA/EE plus metformin.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin improved insulin sensitivity more than CPA/EE plus metformin.
Peptide
Liraglutide
Outcome
IncreaseInsulin sensitivity
Study
n = 60
Comparator
CPA/EE + metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI (Body Mass Index), and waist circumference, FBG(fasting blood glucose), AUCI(area under curve of insulin),TC (Total Cholesterol), IL-6(Interleukin-6) and improving insulin sensitivity, and ovulation in overweight women with PCOS, with acceptable short-term side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321512
13HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, liraglutide plus metformin improved ovulation more than CPA/EE plus metformin.
In plain wordsIn overweight women with PCOS, liraglutide plus metformin improved ovulation more than CPA/EE plus metformin.
Peptide
Liraglutide
Outcome
IncreaseOvulation
Study
n = 60
Comparator
CPA/EE + metformin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI (Body Mass Index), and waist circumference, FBG(fasting blood glucose), AUCI(area under curve of insulin),TC (Total Cholesterol), IL-6(Interleukin-6) and improving insulin sensitivity, and ovulation in overweight women with PCOS, with acceptable short-term side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321513
14HumanRandomized controlled trialSafety outcome
In overweight women with PCOS, liraglutide plus metformin had acceptable short-term side effects over 12 weeks.
In plain wordsIn overweight women with PCOS, the authors judged the short-term side effects of liraglutide plus metformin acceptable.
Peptide
Liraglutide
Outcome
Not applicableShort-term side effects
Study
n = 60
Comparator
CPA/EE + metformin
Outcome group
Adverse events · Whole body
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI (Body Mass Index), and waist circumference, FBG(fasting blood glucose), AUCI(area under curve of insulin),TC (Total Cholesterol), IL-6(Interleukin-6) and improving insulin sensitivity, and ovulation in overweight women with PCOS, with acceptable short-term side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321514
15HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, CPA/EE plus metformin improved hyperandrogenemia markers more than liraglutide plus metformin, which improved only LH.
In plain wordsIn overweight women with PCOS, CPA/EE plus metformin improved male-hormone markers more than liraglutide plus metformin did.
Peptide
Liraglutide
Outcome
MixedHyperandrogenemia markers (testosterone, LH/FSH, SHBG, FAI)
Study
n = 60
Comparator
CPA/EE + metformin
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.2-1.8 mg/day · 12 weeksAs given in this study (human).
Source sentences
Summary
CPA/EE + Met was more effective in improving hyperandrogenemia, including T(total testosterone), LH, LH/FSH(Luteinizing hormone/follicle-stimulating hormone), SHBG(sex hormone-binding globulin) and FAI (free androgen index). By contract, GLP-1RA+Met group only improved LH.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
Show in the study text Report a problemFND-3765321515

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

16HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism
In overweight women with PCOS, plasma proteomic analysis showed that the two treatments (liraglutide plus metformin, and CPA/EE plus metformin) altered proteins involved in reactive oxygen species detoxification, platelet degranulation and the immune response.
In plain wordsIn overweight women with PCOS, the two treatments together changed blood proteins linked to oxidative stress, platelet activity and the immune response.
Peptide
Liraglutide
Outcome
Not applicablePlasma proteome changes
Study
n = 60
Outcome group
Receptor activity and mechanism · Immune and inflammation
Source sentences
Summary
Plasma proteomic analysis revealed that the interventions altered proteins involved in reactive oxygen species detoxification (PRDX6, GSTO1, GSTP1, GSTM2), platelet degranulation (FN1), and the immune response (SERPINB9).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2-1.8 mg/day) +Met (1500 mg/day) for 12 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3765321516

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT03151005

The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS

Xinqiao Hospital of Chongqingn = 701 Jul 2017 to 23 Apr 2021

Polycystic Ovary Syndrome (PCOS) · Overweight · Obesity

Trial page ClinicalTrials.govUpdated 4 Dec 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.